This ASX Stock Is Aiming To Treat A Stroke Long Before The Hospital

What if the fight against stroke-related brain damage could begin before a patient reaches the hospital?

When it comes to stroke treatment, time is critical. In fact, in the medical field, “time is brain” is a common saying when it comes to the treatment of stroke patients.

Strokes can block blood flow to the brain, and the longer the brain goes without blood flow, the greater the risk of lasting damage or even death.

Currently, most stroke treatment occurs only once a patient is in hospital care, but what if paramedics and other first responders could start that treatment much earlier?

That is the possibility being explored by ASX-listed biotechnology company Argenica Therapeutics (ASX:AGN).

Why time and treatment matter so much with strokes

There are two main causes of a stroke.

An ischemic stroke occurs when a clot blocks blood flow in the brain. A haemorrhagic stroke, on the other hand, is caused when a blood vessel bursts, bleeding into the brain, which puts pressure on brain tissue.

One problem is that it takes time to diagnose, and different treatments are required depending on the cause of the stroke.

But the longer it takes to do the necessary imaging tests to diagnose the type of stroke, the higher the risk of lasting injury to the brain or even death. Also, the treatment could exacerbate the problem if you diagnose the cause incorrectly.

Cerebrovascular diseases, of which stroke is the most common form, have been ranked as high as the fourth biggest cause of death in Australia.

What is Argenica Therapeutics developing?

With time being critical when it comes to stroke treatment, the earlier treatment can be provided to help protect the brain, the better.

Argenica is currently trialling a drug, ARG-007, or Xaranetide, which they believe can do just that.

Xaranetide is an experimental drug that aims to protect the brain from damage following a stroke, potentially helping preserve brain function during a critical period when every minute counts. The aim is that this drug would be able to be administered by first responders, such as paramedics, protecting the patient's brain while they are transported to hospital for full diagnosis and treatment.

The company has completed a Phase 1 trial, which proved the safety and tolerability of Xaranetide in healthy human volunteers.

A Phase 2 trial, which was completed in September 2025, also showed that acute ischaemic patients tolerated the medication and that no drug interactions were found. No reduction in damaged brain tissue was found compared to the placebo group. However, there was evidence that it may provide a benefit in certain severity-dependent cases.

What’s next for ASX biotech stock?

The fact that certain stroke patients showed a benefit from Xaranetide has given Argenica optimism to proceed further.

Currently, the company is awaiting approval from the powerful US Food and Drug Administration (FDA).

If the FDA approves, Argenica is set to launch two more trials, including a Phase 2B trial that focuses on Xaranetide’s efficacy in moderate-to-severe acute ischaemic stroke patients, and a Phase 1B trial testing the drug's efficacy in regard to concussion and traumatic brain injuries.

There is no firm date as to when these trials will begin.

As is always the case with biotechnology stocks undergoing clinical trials, there is no guarantee that the product will be successful, and the company is likely going to need further financial support while it undergoes trials before it gets to commercialisation, if it gets there at all. This is why many investors consider investing in such companies high risk.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Andrew Legget and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.